Tagged with Opinion

USA David Crean summarises the mood at the recent J.P. Morgan Healthcare Conference 2020 in San Francisco, noting a more subdued atmosphere than previous years, with reduced attendances and no big M&A announcements. Crean does, however, underline the importance of the Conference for industry networking and highlights some of the biopharma…

Canada John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising North American start-up with a new Parkinson’s disease drug, was recently sold to Germany’s Bayer at a $1 billion valuation.…

Europe Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving biosimilar uptake in Europe.   Since the first treatment was approved in 2006, Europe has been at the vanguard of the biosimilar medicines sector, approving more treatments…

Opinion BIO’s Greg Frank outlines the alarming growth of drug-resistant infections and the steps that need to be taken to combat this rapidly emerging global health threat.   Drug-resistant superbugs are evolving at a rapid pace. In fact, it is estimated that 700,000 people die from drug-resistant infections each year. Without…

USA Eurasia Group’s Aditya Bhattacharji examines the stalling of healthcare reforms in the US and what changes to US healthcare it is realistic to expect.   Pharma is unlikely to be frog-marched by sweeping federal initiatives, but more incremental changes are likely With anti-pharma sentiment raging at the end of 2018,…

Opinion Nigel Hughes of the European Health Data & Evidence Network (EHDEN) outlines EHDEN’s scope and purpose and highlights why greater collaboration on real-world data (RWD) will be crucial to ensuring better global health outcomes.    Ultimately, EHDEN is striving to ensure 21st century research can be conducted with 21st century…

Top PharmaBoardroom featured a wide range of developments in the life sciences industry in 2019, including a growing focus on China and the Asia Pacific region, which shows no signs of slowing down. Furthermore, along with our contributors, we highlighted developments and forecasts in the rare disease and orphan drug space…

Opinion 2019 was a year of innovation and disruption in the life sciences industry. From artificial intelligence to cell and gene therapy, and from generics and biosimilars to geopolitics and healthcare reform, PharmaBoardroom is proud to have collaborated with industry thought leaders to publish their insights on the year’s top trends…

Canada Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada.   Especially in smaller provinces, it’s virtually impossible to predictably manage the affordability and accessibility of drugs necessary to treat rare disease Around the world, rare diseases are becoming easier…

Europe The EFPIA’s Nathalie Moll outlines the case for a new EU-wide industrial strategy with biopharmaceuticals at its heart.   The pharmaceutical industry is an area of strategic economic and social value where the EU is a global player   Europe has a history as a world leader in medical innovation,…

Opinion Becton Dickinson’s Fiona Garín looks at the rise of Healthcare-Acquired Infections (HAIs) in Europe and how an industry-wide culture of safety needs to be developed to counter this growing threat.   Healthcare systems in Europe are becoming more complex in their quest to drive affordability, quality of care and patient…

Opinion The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health Care Costs Act.   A key provision of our generic pharmaceutical architecture is in jeopardy. The “180-day exclusivity” is the…